In vivo CAR T-cell Market Size, Share and Trends Analysis 2025 to 2034

Report Id: 2999 Pages: 180 Last Updated: 31 December 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of In vivo CAR T-cell Market (Potential) -

In vivo CAR T-cell Market (Potential) by Delivery Systems -

in vivo

In vivo CAR T-cell Market (Potential) By Targets

·       Hematological Cancers

o   Multiple Myeloma

o   B-cell Lymphomas (DLBCL, NHL)

o   Acute Lymphoblastic Leukemia (ALL)

·       Solid Tumors

o   Hepatocellular Carcinoma

o   HER2-Positive Solid Tumors

o   Mesothelioma / Ovarian Cancer

o   Neuroblastoma

·       Non-Oncology

o   Systemic Lupus Erythematosus (SLE)

o   Multiple Sclerosis (MS)

In vivo CAR T-cell Market (Potential) By Target Antigen

·       CD19

·       BCMA

·       CD20

·       CD22

·       GPC3

·       HER2

·       Mesothelin (MSLN)

·       GD2

In vivo CAR T-cell Market (Potential) By End-user

·       Hospitals & Cancer Treatment Centers

·       Autoimmune Specialty Clinics

·       Ambulatory Infusion Centers

·       Academic & Research Institutes

                      

In vivo CAR T-cell Market (Potential) by Region-

North America-

  • The US
  • Canada

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Chapter 1.  Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global In vivo CAR T-cell Market (Potential) Snapshot

Chapter 4. Global In vivo CAR T-cell Market (Potential) Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Porter's Five Forces Analysis

4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034

4.8. Global In vivo CAR T-cell Market Penetration & Growth Prospect Mapping (US$ Mn), 2024- 2034

4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)

4.10. Use/impact of AI on In vivo CAR T-cell Market Industry Trends

Chapter 5.In vivo CAR T-cell Market (Potential) Segmentation 1: By Delivery Systems, Estimates & Trend Analysis

5.1. Market Share by Delivery Systems, 2024 & 2034

5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Delivery Systems:

5.2.1. Lipid Nanoparticles (LNPs)

5.2.2. Viral Vectors

5.2.3. Oncolytic Viruses

Chapter 6. In vivo CAR T-cell Market (Potential) Segmentation 2: By Targets, Estimates & Trend Analysis

6.1. Market Share by Targets, 2024 & 2034

6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following

6.2.1. Hematological Cancers

6.2.1.1. Multiple Myeloma

6.2.1.2. B-cell Lymphomas (DLBCL, NHL)

6.2.1.3. Acute Lymphoblastic Leukemia (ALL)

6.2.2. Solid Tumors

6.2.2.1. Hepatocellular Carcinoma

6.2.2.2. HER2-Positive Solid Tumors

6.2.2.3. Mesothelioma / Ovarian Cancer

6.2.2.4. Neuroblastoma

6.2.3. Non-Oncology

6.2.3.1. Systemic Lupus Erythematosus (SLE)

6.2.3.2. Multiple Sclerosis (MS)

Chapter 7. In vivo CAR T-cell Market (Potential) Segmentation 3: By Target Antigen, Estimates & Trend Analysis

7.1. Market Share by Target Antigen, 2024 & 2034

7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Target Antigen:

7.2.1. CD19

7.2.2. BCMA

7.2.3. CD20

7.2.4. CD22

7.2.5. GPC3

7.2.6. HER2

7.2.7. Mesothelin (MSLN)

7.2.8. GD2

Chapter 8. In vivo CAR T-cell Market (Potential) Segmentation 4: By End User, Estimates & Trend Analysis

8.1. Market Share by End User, 2024 & 2034

8.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following End User:

8.2.1. Hospitals & Cancer Treatment Centers

8.2.2. Autoimmune Specialty Clinics

8.2.3. Ambulatory Infusion Centers

8.2.4. Academic & Research Institutes

Chapter 9. In Vivo CAR T-cell Market (Potential) Segmentation 4: Regional Estimates & Trend Analysis

9.1. Global In vivo CAR T-cell Market (Potential), Regional Snapshot 2024 & 2034

9.2. North America

9.2.1. North America In vivo CAR T-cell Market (Potential) Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034

9.2.1.1. US

9.2.1.2. Canada

9.2.2. North America In vivo CAR T-cell Market (Potential) Revenue (US$ Mn) Estimates and Forecasts by Delivery Systems, 2021-2034

9.2.3. North America In vivo CAR T-cell Market (Potential) Revenue (US$ Mn) Estimates and Forecasts by Targets, 2021-2034

9.2.4. North America In vivo CAR T-cell Market (Potential) Revenue (US$ Mn) Estimates and Forecasts by Target Antigen, 2021-2034

9.2.5. North America In vivo CAR T-cell Market (Potential) Revenue (US$ Mn) Estimates and Forecasts by End User, 2021-2034

9.3. Europe

9.3.1. Europe In vivo CAR T-cell Market (Potential) Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034

9.3.1.1. Germany

9.3.1.2. U.K.

9.3.1.3. France

9.3.1.4. Italy

9.3.1.5. Spain

9.3.1.6. Rest of Europe

9.3.2. Europe In vivo CAR T-cell Market (Potential) Revenue (US$ Mn) Estimates and Forecasts by Delivery Systems, 2021-2034

9.3.3. Europe In vivo CAR T-cell Market (Potential) Revenue (US$ Mn) Estimates and Forecasts by Targets, 2021-2034

9.3.4. Europe In vivo CAR T-cell Market (Potential) Revenue (US$ Mn) Estimates and Forecasts by Target Antigen, 2021-2034

9.3.5. Europe In vivo CAR T-cell Market (Potential) Revenue (US$ Mn) Estimates and Forecasts by End User, 2021-2034

9.4. Asia Pacific

9.4.1. Asia Pacific In vivo CAR T-cell Market (Potential) Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034

9.4.1.1. India

9.4.1.2. China

9.4.1.3. Japan

9.4.1.4. Australia

9.4.1.5. South Korea

9.4.1.6. Hong Kong

9.4.1.7. Southeast Asia

9.4.1.8. Rest of Asia Pacific

9.4.2. Asia Pacific In vivo CAR T-cell Market (Potential) Revenue (US$ Mn) Estimates and Forecasts by Delivery Systems, 2021-2034

9.4.3. Asia Pacific In vivo CAR T-cell Market (Potential) Revenue (US$ Mn) Estimates and Forecasts by Targets, 2021-2034

9.4.4. Asia Pacific In vivo CAR T-cell Market (Potential) Revenue (US$ Mn) Estimates and Forecasts by Target Antigen, 2021-2034

9.4.5. Asia Pacific In vivo CAR T-cell Market (Potential) Revenue (US$ Mn) Estimates and Forecasts by End User, 2021-2034

9.4. Rest of World

9.4.1. Rest of World In vivo CAR T-cell Market (Potential) Revenue (US$ Million) Estimates and Forecasts by Delivery Systems, 2021-2034

9.4.2. Rest of World In vivo CAR T-cell Market (Potential) Revenue (US$ Million) Estimates and Forecasts by Target, 2021-2034

9.4.3. Rest of World In vivo CAR T-cell Market (Potential) Revenue (US$ Million) Estimates and Forecasts by Target Antigen, 2021-2034

9.4.6. Rest of World In vivo CAR T-cell Market (Potential) Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034

Chapter 11. Competitive Landscape

11.1. Major Mergers and Acquisitions/Strategic Alliances

11.2. Company Profiles

11.2.1. Umoja Biopharma

11.2.2. Interius BioTherapeutics

11.2.3. Capstan Therapeutics

11.2.4. EsoBiotec

11.2.5. Grit Biotechnology

11.2.6. Kelonia Therapeutics

11.2.7. Orbital Therapeutics

11.2.8. Orna Therapeutics

11.2.9. Ensoma

11.2.10. EXUMA Biotech

11.2.11. Moderna

11.2.12. Sanofi

11.2.13. Tessera Therapeutics

11.2.14. Byterna Therapeutics

11.2.15. Singular Immune

11.2.16. NanoCell Therapeutics

11.2.17. Jenthera Therapeutics

11.2.18. Pregene

11.2.19. Abintus Bio

11.2.20. Legend Biotech

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
9721
Security Code field cannot be blank!

Frequently Asked Questions

In vivo CAR T-cell Market Size is predicted to grow at a 32.9% CAGR during the forecast period for 2025-2034.

Interims BioTherapeutics, Capstan Therapeutics, Esobiotec (AstraZeneca), Poseida Therapeutics, Umoja Biopharma, ORNA Therapeutics, Vyriad (in collabor

In vivo CAR T-cell market is segmented by delivery systems and targets.

North America region is leading the In vivo CAR T-cell Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying